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Abstract
Background: Generic antiretroviral therapy is the mainstay of HIV treatment in resource-limited settings, yet there is little
evidence confirming the bioequivalence of generic and brand name formulations. We compared the steady-state
pharmacokinetics of lamivudine, stavudine and nevirapine in HIV-infected subjects who were receiving a generic
formulation (TriomuneH) or the corresponding brand formulations (EpivirH, ZeritH, and ViramuneH).
Methodology/Principal Findings: An open-label, randomized, crossover study was carried out in 18 HIV-infected Ugandan
subjects stabilized on Triomune-40. Subjects received lamivudine (150 mg), stavudine (40 mg), and nevirapine (200 mg) in
either the generic or brand formulation twice a day for 30 days, before switching to the other formulation. At the end of
each treatment period, blood samples were collected over 12 h for pharmacokinetic analysis. The main outcome measures
were the mean AUC0–12h and Cmax. Bioequivalence was defined as a geometric mean ratio between the generic and brand
name within the 90% confidence interval of 0.8–1.25. The geometric mean ratios and the 90% confidence intervals were:
stavudine Cmax, 1.3 (0.99–1.71) and AUC0–12h, 1.1 (0.87–1.38); lamivudine Cmax, 0.8 (0.63–0.98) and AUC0–12h, 0.8 (0.65–0.99);
and nevirapine Cmax, 1.1 (0.95–1.23) and AUC0–12h, 1.1 (0.95–1.31). The generic formulation was not statistically
bioequivalent to the brand formulations during steady state, although exposures were comparable. A mixed random effects
model identified about 50% intersubject variability in the pharmacokinetic parameters.
Conclusions/Significant Findings: These findings provide support for the use of Triomune in resource-limited settings,
although identification of the sources of intersubject variability in these populations is critical.
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Introduction
Generic drugs provide patients with lower-cost alternatives to
the more costly brand name drugs. Production of more
affordable generic antiretroviral medications (ARVs) has greatly
boosted global efforts to scale up access to these life-saving
medications. Today, more than half of all ARV prescriptions in
sub-Saharan Africa are filled with generic drugs. The use of
generics has resulted in substantial savings to consumers and
governments. These drugs have dramatically reduced the
morbidity and mortality due to HIV/AIDS, and drug quality
is a key factor in attaining the long term goals of sustained viral
suppression with minimal drug resistance. TriomuneH, a fixed-
dose generic combination of lamivudine, stavudine and nevir-
apine, has been shown to be bioequivalent to its innovator
counterparts (EpivirH, ZeritH and ViramuneH) in a single dose
study in healthy Indian volunteers [1]. However, drug pharma-
cokinetics and pharmacodynamics may vary in ethnically distinct
populations of HIV-infected patients. Furthermore, since this is
chronic therapy, there is a need to evaluate the steady-state
pharmacokinetics of these drugs in the target population. A study
conducted in Malawian HIV-infected adults showed that
Triomune was not strictly bioequivalent to its innovator cousins
at steady state [2], but this has not been replicated in other
populations. Assurance of continual exposure to optimal plasma
concentrations of these medications is essential to avoid the
development of drug resistance resulting from sub therapeutic
plasma concentrations. The goal of this study was to compare the
pharmacokinetics of Triomune and its innovator counterparts in
HIV-infected Ugandans with advanced disease. In addition, we
sought to investigate the source of variation in pharmacokinetic
parameters.
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Materials and Methods
Ethics committee review and informed consent
The study protocol and informed consent forms were reviewed
and approved by the Makerere University Faculty of Medicine
Ethics Committee and the University of California San Francisco
Committee on Human Research. All subjects provided written
informed consent prior to participation in the study.
Study setting and subject selection
Subjects were recruited from an ongoing cohort study (Adher-
ence Monitoring Uganda (AMU)) in Kampala, Uganda. AMU was
an observational study of adherence and treatment response among
individuals on self-pay HIV generic antiretroviral therapy conduct-
ed from 2002–2007 [3,4]. AMU cohort members with a body
weight of 60 kg or greater were approached by a member of the
research team and invited to participate in the bioequivalence study;
those who were interested and fulfilled other selection criteria were
enrolled into the study. Subjects received quarterly adherence
assessments using unannounced home pill count, Medication Event
Monitoring System (MEMS) and laboratory monitoring of CD4 T
cells, HIV RNA, and hematological function. All subjects had been
taking Triomune-40 (stavudine 40 mg, lamivudine 150 mg,
nevirapine 200 mg) twice daily for at least three years. Most of
the subjects attended the Infectious Diseases Clinic in Mulago,
Uganda. Mulago Hospital is the main teaching and referral hospital
in Uganda and the Infectious Diseases Clinic is a specialized HIV/
AIDS clinic that treats over 13,000 patients, ,5000 of whom
receive antiretroviral therapy.
Participants received a medical and laboratory examination no
less than seven days prior to enrollment in this pharmacokinetic
sub-study to exclude active opportunistic infections. A urine
pregnancy test was performed on all women participants. Subjects
were excluded if they had active tuberculosis, were taking drugs
known to interefere with the metabolism or transport of the study
drugs (rifampicin, cimitedine, erthyromycin, ketoconazole, carba-
mazepine, phenobarbitone and phenytoin), had gastrointestinal
problems, hepatitis, hemoglobin less than 7 mmol/L for men and
6.5 mmol/L for women, liver and renal function test results 5 or
1.5 times the upper limit of normal, respectively, or were pregnant.
We also excluded those patients who expected to change their
regimen or move out of the study area within two months.
Subjects on daily cotrimoxazole (trimethoprim/sulfamethoxazole)
prophylaxis were included.
Study design
This study utilized an open-label, randomized, crossover design
comparing the pharmacokinetics of generic and trade formulations
of stavudine, lamivudine and nevirapine under fed conditions.
Subjects were randomized to one of two formulations. Formula-
tion 1 (generic) was a single tablet containing lamivudine (150 mg),
stavudine (40 mg) and nevirapine (200 mg) (Triomune-40).
Formulation 2 (brand) was a single tablet of lamivudine
(150 mg, Epivir) plus one 40 mg tablet of stavudine (Zerit) and
one 200 mg tablet of nevirapine (Viramune). Each formulation
was taken twice daily. Seven subjects were randomized to the
generic-to-brand arm and 11 were randomized to the brand-to-
generic arm. Subjects took each formulation for 30 days prior to
pharmacokinetic sampling. The generic formulation (Triomune-
40) was manufactured by Cipla (Mumbai, India) and the brand
formulations by: Zerit, Bristol- Myers Squibb, Princeton, NJ,
USA; Epivir, GlaxoSmithKline, Middlesex, United Kingdom and
Viramune, Boehringer Ingelheim, Ingelheim am Rhein, Ger-
many. The study was conducted between March and May, 2006.
Study procedures
To monitor adherence, study drugs were dispensed to the
participants in a bottle with an electronic cap that recorded each
pill bottle opening using the Medication Event Monitoring System
(MEMS) (Aardex. (2004), Union City, CA). In addition, the pills
were counted and the number recorded manually at each visit.
Adherence was also assessed by a 3-day self report and 30-day
visual analogue scale [3].
Participants were admitted to the hospital ward the night before
the pharmacokinetic sampling and administration of the 8 p.m.
evening dose was witnessed by research staff. Participants were fasted
overnight and were instructed not to take their morning dose(s) or eat
until the first blood sample had been drawn the next day.
Each subject had an indwelling catheter inserted into an arm
vein for drawing serial blood samples. A 6 ml blood sample was
obtained before antiretroviral medications were administered
(t = 0 hr) during a witnessed dose at 8 a.m. Additional 6 ml blood
samples were obtained at 0.5, 1, 1.5, 2, 3, 4, 6, 10 and 12 hr post-
dosing. Food and water intake were controlled during the study.
After the 12 hr sample collection participants were given the
alternate formulation in a MEMS bottle and asked to report back
to the clinic after 30 days. At the next visit, identical procedures
were repeated.
Blood samples were collected in vacutainer tubes containing
EDTA as the anticoagulant. Blood samples were immediately
delivered to the Makerere University Johns Hopkins University
Collaboration (MUJHU) laboratory where plasma was separated
by centrifugation at 900g for 10 min and then stored at 270uC
until analysis. Samples were transported in a single batch on dry
ice to the Department of Biopharmaceutical Sciences at the
University of California San Francisco for analysis.
Analysis of plasma samples
Prior to drug extraction, plasma samples (including controls) were
heated at 56˚C for 90 min to inactivate virus. Heat treatment was
determined to have no quantifiable effect on drug stability or
concentration. Drug concentrations were analyzed using a method
reported previously [5]. Briefly, stavudine, lamivudine, and
nevirapine were extracted simultaneously from 0.5 ml of plasma
using solid-phase extraction columns (Oasis HLB Extraction
Cartridges, Waters Corporation, Milford, Massachusetts, USA)
and eluted with 1 ml of mobile phase, consisting of 0.1% glacial
acetic acid in acetonitrile:water (80:20, v/v). Metaxalone was used
as an internal standard. Samples were subjected to LC/MS/MS on
an API 4000 system (Applied Biosystems, Foster City, California,
USA) using a Waters 717plus autosampler and a Symmetry C18
(150 mm63.9 mm i.d., 5 mm particle size, Waters Corporation)
analytical column. The flow rate was 0.4 ml/min. All peaks were
quantified using multiple reaction monitoring (MRM) mode to
study the conversions from parent to product ion (m/z), and data
were collected using Analyst version 1.4 (Applied Biosystems). The
precision of the assay, as measured by the interassay coefficient of
variation of control samples, was ,13.2%, ,15.2%, and ,14.8%
for stavudine, lamivudine, and nevirapine, respectively.
Pharmacokinetic analysis
Pharmacokinetic parameters were determined from plasma
concentrations based on a non-compartmental model with
extravascular input (Model 200) using WinNonLin software,
version 5.2 (Pharsight Corporation, Mountain View, CA, USA).
The AUC was calculated using the log-linear trapezoidal rule, in
which the linear trapezoidal rule was used up to Cmax, and
thereafter the logarithmic trapezoidal rule was used. Cmax and tmax
were directly observed from the concentration-time data. Geo-
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metric mean ratios (GMR) and 90% confidence intervals (CI) for
AUC0–12h and Cmax were used in the determination of
bioequivalence, as defined by a 90% CI range of 0.80–1.25.
Statistical Analyses
A sample size of 18 subjects was estimated using a formula by
Zhang et al. [6] to provide 80% power to detect approximately a
20% difference on a log scale in AUC0–12h and Cmax between the
brand formulation and the generic formulation. Power was based
on findings from an earlier study [1] in which the coefficients of
variability (CV) for stavudine, lamivudine and nevirapine AUC
were 16%, 18% and 21%, respectively.
Primary parameters for statistical analyses were AUC0–12h and
Cmax of lamivudine, stavudine and nevirapine and their intra- and
intersubject variances. Differences between treatments with
respect to AUC0–12h, Cmax and intra- and intersubject variances
were assessed using the mixed random effects model. In particular,
we used the simple random intercept model with bootstrapped
standard errors because the drug concentrations, even after log
transformation, were not normally distributed. The model
employed for this study included sequence, period, and treatment
as fixed effects and subjects (nested within sequence) as the random
effects. The primary analysis was conducted on log-transformed
(base e) AUC0–12h and Cmax. Measured values of C0h and C12h
were compared to assess the presence of steady-state conditions
and to evaluate adherence.
Results
Subjects
Twenty HIV-positive adults (8 males, 12 females) were enrolled in
the study. Two subjects were excluded from the analysis because their
plasma samples were not sufficient for pharmacokinetic analysis. The
analysis therefore includes 18 participants. Participants ranged from
28 to 50 years of age (mean6SD; 37.466.0), weighed 68.366.6 kg,
averaged 16569.4 cm in height, and had a mean body mass index of
25.163.4 kg/m2. Patient characteristics did not differ between
randomization arms (Table 1). All participants had been on the
generic lamivudine/stavudine/nevirapine formulation for at least 36
months. Ten participants were taking prophylactic cotrimoxazole
during the study. All subjects were physically healthy based on their
medical examination and results from clinical laboratory tests. No
tuberculosis, malabsorption, nausea, emesis, abdominal discomfort,
chronic diarrhea, or hepatitis was reported. All females had a
negative pregnancy screen.
Adherence and steady-state drug concentration
Based on MEMS adherence records, mean adherence for the 30
days prior to the first and second pharmacokinetic study visits was
99.7% and 99.0%, respectively. Fifteen out of eighteen subjects had
100% adherence before the first pharmacokinetic sampling and
sixteen out of eighteen subjects had 100% adherence before the
second pharmacokinetic sampling. Each of the three subjects with
incomplete adherence before the first pharmacokinetic sampling
had 98% adherence and of the two subjects with incomplete
adherence before the second pharmacokinetic sampling, one had
95% while the other had 88% adherence. In addition to the MEMS
and pill count we also did a three day self report on the morning of
the pharmacokinetic sampling asking about adherence over the
previous three days. For each of these participants, three day self
reported adherence prior to pharmacokinetic sampling was 100%
and the MEMS report showed that all doses had been taken in the
week preceding pharmacokinetic sampling for two subjects. For the
subject with 88% adherence at the second pharmacokinetic draw,
the MEMS report showed that he had taken only 9 out of 14
prescribed doses. For the remaining two subjects with incomplete
adherence [95% and 98%] non-adherence did not occur
immediately prior to pharmacokinetic sampling.
Trough plasma concentrations in each subject prior to the study
dose of medication for each period were determined to confirm
steady state conditions. All patients had measurable levels of each
drug prior to administration of both the generic and brand
formulations. Mean trough plasma concentrations were similar for
generic and brand lamivudine and stavudine, but trough
nevirapine concentrations were significantly higher with the
generic formulation during period 2 (Table 2).
Bioequivalence Evaluation
The mean concentration-time profiles over 12 hours for each
drug after administration of the generic and brand formulations
Table 1. Baseline characteristics of participants according to randomization arm.
GenericRBrand BrandRGeneric
Number 7 11
Mean age [years(SD)] 35.3 (5.3) 38.8 (6.3)
Sex (M/F) 3/4 4/7
Mean weight [kg (SD)] 68.4 (10.2) 68.2 (3.8)
Mean height [cm (SD)] 163 (8.7) 167 (9.8)
Mean body mass index [kg/m2 (SD)] 26.0 (4.4) 24.5 (2.8)
Mean HIV RNA [log10 copies/ml (SD)] 2.8 (0.6) 2.8 (0.5)
HIV RNA,400 copies/ml [n (%)] 5 (71.4) 10 (90.9)
Mean CD4 T cell count [cells/ml (SD)] 319 (116) 402 (267)
Mean Hemoglobin [mmol/l (SD)] 14.7 (1.5) 13.8 (1.9)
Mean alanine aminotransferase [U/L (SD)] 26.7 (7.34) 30.8 (18.2)
Mean aspartate aminotransferase [U/L (SD)] 27.7 (8.9) 29.9 (8.54)
Mean serum creatinine [mg/dL (SD)] 1.1 (0.1) 0.9 (0.2)
On prophylactic cotrimoxazole [n (%)] 5 (71.4) 5 (45.5)
doi:10.1371/journal.pone.0003981.t001
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are shown in Figure 1. There is little noticeable variation in plasma
levels of stavudine or nevirapine between the brand and generic
formulations. In contrast, lamivudine levels are much higher
following the dosing of the brand name formulation compared to
the generic. As expected based on its long half-life, nevirapine
levels were relatively constant during the 12 hr study period.
Both AUC0–12h and Cmax were analyzed as bioequivalence
markers. The geometric mean ratios for AUC0–12h were close to
unity for all three compounds, suggesting similar exposure with the
two formulations. The largest variation was seen for lamivudine,
with a 20% reduction in exposure with the generic formulation.
The FDA definition for bioequivalence of a 90% confidence
interval of the geometric mean ratio between 0.8 and 1.25 is not
met for AUC0–12h for any of these drugs. Similar results were
found for Cmax, with nevirapine being the only drug that meets the
bioequivalence criteria (GMR = 1.1, 90% CI 0.95–1.23) (Table 3).
For lamivudine, the Cmax was 20% lower with the generic
compared to the brand formulation while for stavudine the Cmax
was 30% higher with the generic compared to the brand
formulation. Because the concentration-time profiles (Fig. 1) are
drawn on an ordinary scale the difference in Cmax for stavudine is
not very noticeable given that the arithmetic means for the brand
and generic were very close.
A mixed random effects model demonstrated significant
sequence effects for both nevirapine log transformed Cmax
(p,0.0001) and AUC (p,0.0001) as outcomes. Intersubject
variability for log transformed Cmax ranged from 0.24–0.40 and
that for AUC ranged from 0.23–0.42. Intrasubject variability for
Cmax ranged from 0.21–0.44 and AUC ranged from 0.25–0.36
(Table 4). Intersubject variability accounts for approximately half
of the variability in the Cmax and AUC estimates.
Discussion
We found generic stavudine, lamivudine and nevirapine in the
form of Triomune fails to meet strict bioequivalence criteria in
patients with objectively confirmed adherence on stable therapy.
While Triomune failed to meet strict bioequivalence, the
differences were relatively minor and are unlikely to be clinically
significant. Our results are similar to a recently reported
bioequivalence study carried out in Malawian HIV-infected
patients [2]. One exception is that in the former study, the
generic Triomune formulation resulted in a significant increase in
stavudine Cmax compared to the brand name. In both the present
study and in the Malawian report, plasma levels of nevirapine
following administration of either the generic or brand formula-
tions were higher than those previously reported in Caucasian
HIV patients [2,7]. A large fraction of nevirapine is metabolized
by the polymorphic CYP2B6 enzyme [8,9]. Whether the elevated
levels of nevirapine in these African populations is related to the
higher allele frequency of the reduced function CYP2B6 516G.T
polymorphism in these populations should be investigated in larger
samples.
There are several reasons why the differences in drug exposure
between brand and generic medication are unlikely to be clinically
significant. Over 70% achieved undetectable viral load levels
Table 2. Trough plasma concentrations prior to initiation of
pharmacokinetic study.
Plasma Concentration (ng/ml)a P-value
Brand Generic
Period 1
3TC 3036270 2126160 0.43
D4T 1956342 1616245 0.86
NVP 823064270 616061890 0.25
Period 2
3TC 4686486 3916405 0.72
D4T 2836331 5116547 0.44
NVP 47706952 930063640 0.01
aPlasma concentrations are expressed as mean6SD.
doi:10.1371/journal.pone.0003981.t002
Figure 1. Plasma concentration-time profiles for brand and
generic stavudine, lamivudine and nevirapine. Mean plasma
concentration-time profiles of (A) stavudine, (B) lamivudine and (C)
nevirapine in 18 subjects after oral administration of brand (closed
symbol) or generic (open symbol) formulation. Each value represents
the arithmetic mean6SE for 18 subjects in each arm.
doi:10.1371/journal.pone.0003981.g001
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(,400 copies/ml) and had significantly improved their CD4 count
at 12 and 24 weeks [3,4]. Even in the case of lamivudine, for which
Cmax and AUC were decreased 20–30% with the generic
formulation compared to brand name, the plasma concentrations
were similar to those reported following a single dose of Triomune
or a second combination drug containing abacavir, lamivudine
and zidovudine to healthy subjects [1,10]. Furthermore, the mixed
random effects model found no statistically significant difference in
Cmax or AUC between the formulation types for any of the three
drugs (results not shown).
We found a high degree of variability between study subjects. The
random effects model produced correlation coefficients of about
50% for both log transformed Cmax and AUC values (Table 4). This
implies that about 50% of all variability in these parameters was due
to differences between study subjects. The interindividual variability
in the pharmacokinetics of stavudine, lamivudine, and nevirapine
may be attributable to various sources, such as environmental or
genetic factors, that were not addressed in this study. In particular,
genetic polymorphisms in transporters or drug-metabolizing
enzymes for which these drugs are substrates may affect the
pharmacokinetics of these drugs. For example, the cytochrome
P450 2B6 (CYP2B6) enzyme, which is involved in nevirapine
metabolism, contains a genetic polymorphism (516G.T) that has
been shown to substantially decrease hepatic protein expression and
function [11]. In patients with HIV, this polymorphism has been
significantly associated with increased nevirapine plasma levels [12].
While the nucleoside reverse transcriptase inhibitors lamivudine
and stavudine are not extensively metabolized in the liver, it is
possible that polymorphisms in membrane transporters could
influence the bioavailability of lamivudine and stavudine, thereby
modulating plasma drug levels. Recently, a polymorphism in the
MRP4 transporter was associated with intralymphocytic lamivudine
levels in HIV patients [13]; conceivably, this polymorphism may
similarly affect MRP4 activity in enterocytes, where drug absorption
occurs. Due to the relatively small minor allele frequencies of these
polymorphisms, a larger study population is needed to address these
pharmacogenetic questions.
We observed a significant difference in the mean nevirapine
trough concentrations between the brand and the generic
formulation. However, these steady state plasma nevirapine
concentrations are far above the concentration required to inhibit
50% viral replication in vitro; the IC50 for nevirapine is 10.6 ng/ml
[14] so this difference may not have clinical relevance. The first
round of pharmacokinetic sampling does not show a significant
difference in the mean nevirapine trough concentrations between
the brand and generic formulation. This implies that the observed
difference is not a systematic difference in the trough concentra-
tions of the two formulations and may be due to the observed
sequence effects. A limitation of our study was that we did not
conduct drug content assays and in vitro dissolution tests. A drug
content assay for each formulation would rule out formulation
problems. In vitro dissolution testing would reveal variations in
drug degradation between brand and generic formulations that
could lead to in vivo differences in the rate of nevirapine absorption.
Table 3. Pharmacokinetic parameters of generic and brand name nevirapine, stavudine and lamivudine.
Pharmacokinetic Parametera Arithmetic Mean
b Geometric Meanb GMRc
Generic Brand Generic Brand
Nevirapine
Cmax (mg/L) 9.263.1 9.665.5 8.863.1 8.465.5 1.1 (0.95–1.23)
AUC0–12h (h*mg/L) 91.5635.2 88.2645.7 85.8635.2 79.2645.7 1.1 (0.95–1.31)
tmax (h) 1.861.8 2.162.6
Lamivudine
Cmax (mg/L) 1.160.5 1.761.4 1.060.5 1.361.4 0.8 (0.63–0.98)
AUC0–12h (h*mg/L) 5.662.5 7.564.9 5.262.5 6.464.9 0.8 (0.65–0.99)
tmax (h) 1.160.8 1.260.6
Stavudine
Cmax (mg/L) 1.961.1 1.862.0 1.661.1 1.362.0 1.3 (0.99–1.71)
AUC0–12h (h*mg/L) 4.162.4 4.263.9 3.662.4 3.463.9 1.1 (0.87–1.38)
tmax (h) 0860.5 1.160.8
aAbbreviations used are Cmax, maximum plasma concentration, AUC, area under the concentration-time curve, and tmax, time to maximum plasma concentration.
bPharmacokinetic parameters are given as the mean6SD.
cGMR, geometric mean ratio; the 90% confidence interval is given in parentheses.
doi:10.1371/journal.pone.0003981.t003
Table 4. Inter- and intrasubject variability in log transformed
pharmacokinetic parameters.
Intersubject
Variabilitya
Intrasubject
Variabilitya
Correlation
Coefficient (r)b
logCmax
Lamivudine 0.37 0.34 0.53
Stavudine 0.40 0.44 0.46
Nevirapine 0.24 0.21 0.57
logAUC0–12
Lamivudine 0.33 0.33 0.50
Stavudine 0.42 0.36 0.57
Nevirapine 0.23 0.25 0.46
aInter- and intrasubject variability indicate the standard deviation of the
pharmacokinetic parameters between or within subjects, respectively.
br is the proportion of the total variability that is due to the variability between
subjects.
doi:10.1371/journal.pone.0003981.t004
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Our analysis model identified significant sequence effects for
nevirapine Cmax and AUC. Although the exact causes of the
sequence effects are not known, ‘real’ differences between the
groups could contribute to the observed effects. While our study
groups were similar in most baseline characteristics, the brand to
generic group was generally healthier than the generic to brand
group. Ninety one percent (10/11) of the brand to generic group
was virologically suppressed (,400 copies/ml) compared to 71%
(5/7) in the generic to brand group (Table 1). In addition, mean
CD4 cell count in the brand to generic group was about 80 units
more than the mean CD4 count in the generic to barnd group
(402 cells/ml vs. 319 cells/ml). To control for this empirical
confounding, baseline CD4 cell count and viral load were added
to the model. We found a significant association between baseline
CD4 cell count and nevirapine Cmax (p = 0.007) and AUC
(p = 0.02). Higher CD4 cell count was associated with lower drug
levels. This difference in health status may explain the observed
sequence effects.
Triomune-40H contains a higher dose of stavudine than is
currently recommended in treatment guidelines. Current WHO
guidelines now recommend a 12 hourly dose of 30 mg for all
patients, irrespective of weight [15]. This limits applicability of our
results to patients currently on antiretroviral therapy. Studies
exploring bioequivalence of fixed dose combination formulations
containing 30 mg of stavudine are needed.
In summary, the steady-state pharmacokinetics of the generic
formulation (Triomune-40H) in HIV-infected patients did not
meet the strict bioequivalence requirement set by the FDA when
compared to the brand name formulations of lamivudine,
stavudine, and nevirapine. However, based on the measured
plasma levels, the generic formulation is expected to produce a
similar therapeutic response as the brand name formulations.
There was a large degree of interindividual variability in
antiretroviral exposure. Variability could have been due to
individual disease state and progression, or the genetic variation
within the subjects. Understanding the exact sources of this
variability will be important for optimization of therapy. These
results suggest that bioequivalence and pharmacokinetic studies
are needed in specific populations in which these medications are
used, to account for unique characteristics that may influence drug
disposition. Drug regulatory bodies in countries in which generic
antiretroviral medications are used should endeavor to test all
antiretrovirals imported into the country to ensure drug quality.
Acknowledgments
The authors thank Dr. Pauline Byakika-Kibwika for conducting all the
medical examinations on the study participants during the screening phase
and doing the clinical monitoring during the pharmacokinetic sampling,
Mary Kasango and Annet Kawuma for drawing the blood samples, Irene
Zawedde for managing the study data, Sarah Nakandi for ensuring
adequate availability of all the study requirements and Ibrahim Kiviri for
transporting participants from their homes to the hospital ward, and Yong
Huang for advice on the LC/MS/MS assay. Special thanks go to all the
patients that participated in this study.
Author Contributions
Conceived and designed the experiments: JBT JHO CO DRB. Performed
the experiments: JBT LWC JHO CO. Analyzed the data: JBT LWC DLK.
Wrote the paper: JBT LWC DRB DLK. Supervised all analysis: DLK.
References
1. Narang VS, Lulla A, Malhotra G, Purandare S (2005) A combined-formulation
tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with
concurrent administration of lamivudine, nevirapine, and stavudine in healthy
Indian subjects. J Clin Pharmacol 45: 265–274.
2. Hosseinipour MC, Corbett AH, Kanyama C, Mshali I, Phakati S, et al. (2007)
Pharmacokinetic comparison of generic and trade formulations of lamivudine,
stavudine and nevirapine in HIV-infected Malawian adults. AIDS 21: 59–64.
3. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, et al.
(2004) Multiple validated measures of adherence indicate high levels of
adherence to generic HIV antiretroviral therapy in a resource-limited setting.
J Acquir Immune Defic Syndr 36: 1100–1102.
4. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, et al.
(2007) Treatment interruptions predict resistance in HIV-positive individuals
purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.
AIDS 21: 965–971.
5. Mistri HN, Jangid AG, Pudage A, Gomes N, Sanyal M, et al. (2007) High
throughput LC-MS/MS method for simultaneous quantification of lamivudine,
stavudine and nevirapine in human plasma. J Chromatogr B Analyt Technol
Biomed Life Sci 853: 320–332.
6. Zhang P (2003) A simple formula for sample size calculation in equivalence
studies. J Biopharm Stat 13: 529–538.
7. von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, et al. (2006) A
comparison of the steady-state pharmacokinetics of nevirapine in men,
nonpregnant women and women in late pregnancy. Br J Clin Pharmacol 62:
552–559.
8. Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, et al. (2007)
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma
concentrations in HIV-infected patients in Uganda. HIV Med 8: 86–91.
9. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, et al. (2007) CYP2B6
genetic variants are associated with nevirapine pharmacokinetics and clinical
response in HIV-1-infected children. Aids 21: 2191–2199.
10. Yuen GJ, Lou Y, Thompson NF, Otto VR, Allsup TL, et al. (2001) Abacavir/
lamivudine/zidovudine as a combined formulation tablet: bioequivalence
compared with each component administered concurrently and the effect of
food on absorption. J Clin Pharmacol 41: 277–288.
11. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, et al. (2001) Extensive
genetic polymorphism in the human CYP2B6 gene with impact on expression
and function in human liver. Pharmacogenetics 11: 399–415.
12. Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, et al. (2008) Impact
of CYP2B6 983T.C polymorphism on non-nucleoside reverse transcriptase
inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Che-
mother 61: 914–918.
13. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV (2006)
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine
therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr
42: 441–449.
14. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, et al. (1995)
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients
with human immunodeficiency virus infection. J Infect Dis 171: 537–545.
15. World Health Organization Guidelines Development Group (2007) Important:
Addendum to 2006 WHO Guidelines on Antiretroviral Therapy for HIV Infection
in Adults and Adolescents. http://www.who.int/hiv/art/ARTadultsaddendum.
pdf.
ARV Bioequivalence in Uganda
PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e3981
